Polar Asset Management Partners Inc. Purchases 216,400 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Polar Asset Management Partners Inc. lifted its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 122.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 393,000 shares of the company’s stock after purchasing an additional 216,400 shares during the period. Polar Asset Management Partners Inc. owned 0.13% of Amneal Pharmaceuticals worth $3,270,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Bellevue Group AG increased its holdings in shares of Amneal Pharmaceuticals by 21.8% in the third quarter. Bellevue Group AG now owns 76,414 shares of the company’s stock valued at $636,000 after purchasing an additional 13,654 shares in the last quarter. Walleye Capital LLC acquired a new stake in shares of Amneal Pharmaceuticals in the third quarter valued at approximately $1,095,000. FMR LLC increased its holdings in shares of Amneal Pharmaceuticals by 25.9% in the third quarter. FMR LLC now owns 203,510 shares of the company’s stock valued at $1,693,000 after purchasing an additional 41,882 shares in the last quarter. Quantbot Technologies LP increased its holdings in shares of Amneal Pharmaceuticals by 274.8% in the third quarter. Quantbot Technologies LP now owns 111,181 shares of the company’s stock valued at $925,000 after purchasing an additional 81,519 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Amneal Pharmaceuticals by 16.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,404,883 shares of the company’s stock valued at $11,689,000 after purchasing an additional 202,863 shares in the last quarter. Institutional investors and hedge funds own 31.82% of the company’s stock.

Amneal Pharmaceuticals Stock Up 3.3 %

Shares of NASDAQ AMRX opened at $8.81 on Thursday. The stock has a market cap of $2.73 billion, a price-to-earnings ratio of -12.96 and a beta of 1.12. Amneal Pharmaceuticals, Inc. has a twelve month low of $4.46 and a twelve month high of $9.48. The company’s fifty day moving average is $8.54 and its 200-day moving average is $7.82.

Insider Activity at Amneal Pharmaceuticals

In related news, SVP Jason B. Daly sold 43,657 shares of the business’s stock in a transaction on Friday, November 15th. The shares were sold at an average price of $8.61, for a total value of $375,886.77. Following the sale, the senior vice president now directly owns 13,665 shares of the company’s stock, valued at approximately $117,655.65. The trade was a 76.16 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 17.46% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts have commented on AMRX shares. StockNews.com raised shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday, November 11th. Truist Financial lifted their target price on shares of Amneal Pharmaceuticals from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Wednesday, October 2nd. Piper Sandler lifted their target price on shares of Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an “overweight” rating in a report on Monday, November 11th. Barclays lifted their target price on shares of Amneal Pharmaceuticals from $8.00 to $10.00 and gave the stock an “overweight” rating in a report on Tuesday, August 13th. Finally, JPMorgan Chase & Co. raised shares of Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 target price for the company in a report on Friday, September 6th. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $10.00.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.